Dɔdamɔnu vovovowoe li woate ŋu azã na tsinyegoe me kansa, eye esia nɔa te ɖe eƒe tsitsi kple eƒe sesẽ dzi, kpakple dɔnɔa ƒe lãmesẽ kple eƒe didiwo dzi.
Atike siwo bɔ dometɔ aɖewoe nye:
1. Ŋkuléle Ðe Dɔlélea Ŋu Nyuie: Mɔ sia bia be woanɔ ŋku lém ɖe kansa la ŋu nyuie to edodokpɔ kple dodokpɔwo wɔwɔ edziedzi me, ke menye be woadze dɔdada gɔme enumake o.
Ate ŋu asɔ na ŋutsu siwo ŋu tsinyegoe me kansa mebɔ ɖo o.
2. Dɔwɔwɔ: Dɔwɔwɔ si me woɖea tsinyegoe le enye dɔ si me woɖea tsinyegoe le.
Woate ŋu awɔe to amekoƒe si le ʋuʋu alo laparoscopic (si me woɖea nu suewo le eye wozãa dɔwɔnu tɔxɛwo le) dzi.
3. Dɔdamɔnu si nye keklẽŋusẽ: Dɔdamɔnu sia zãa keklẽŋusẽ gã aɖe tsɔ wua kansa me nugbagbeviwo.
Woate ŋu atsɔe ade lãme na amea (to mɔ̃ aɖe si le ŋutilãa godo dzi) alo atsɔe ade lãme nɛ (to nutete aɖe si woade ɖe nutetea ŋu me).
4. Lãmetsiwo zazã: Atikewɔwɔ sia ɖea ŋutsu ƒe lãmetsi (androgen) siwo le ŋutilãa me dzi kpɔtɔna, si ate ŋu ana tsinyegoe me kansa la nagatsi kabakaba alo atsi enu kura.
Woate ŋu azãe le eɖokui si alo atsɔe akpe ɖe atike bubuwo ŋu.
5. Dɔdamɔnu si nye atikewo zazã atsɔ ada kansa: Dɔdamɔnu sia zãa atikewo tsɔ wua kansa lãmenugbagbeviwo.
Woate ŋu azãe le tsinyegoe me kansa si kaka ɖe ŋutilã ƒe akpa bubuwo ŋu la me.
6. Dɔlélenutsitsiŋusẽdɔ: Dɔdamɔnu sia kpena ɖe dɔlélenutsitsiŋusẽ ŋu wòtsia kansa nu.
Woate ŋu azãe le tsinyegoe me kansa si nu sẽ si ŋu dɔdamɔnu bubuwo mewɔ o la me.
7. Dɔdamɔnu si woɖona ɖe ame koŋ ŋu: Dɔdamɔnu sia ƒe taɖodzinue nye be wòana domenyiŋusẽfianu alo protein aɖewo siwo kpena ɖe kansa me lãmenugbagbeviwo ŋu be woatsi ahatsi la naxɔ dɔ.
Woate ŋu azãe le tsinyegoe me kansa si nu sẽ si ŋu dɔdamɔnu bubuwo mewɔ o la me.
8. Dɔdamɔnu si nye Cryotherapy: Dɔdamɔnu sia zãa vuvɔ si nu sẽ ŋutɔ tsɔ tsia kansa me lãmenugbagbeviwo eye wòwua wo.
Woate ŋu azãe le tsinyegoe me kansa si dze egɔme teti alo esi gatrɔ va le dɔdamɔnu bubuwo megbe la ŋu.
9. Dɔdamɔnu si nye High-intensity focused ultrasound (HIFU): Dɔdamɔnu sia zãa gbeɖiɖi si ƒona sesĩe tsɔ doa dzo lãmenugbagbevi siwo me kansa le eye wòtsrɔ̃a wo.
Woate ŋu azãe le tsinyegoe me kansa si dze egɔme teti alo esi gatrɔ va le dɔdamɔnu bubuwo megbe la ŋu.
10. Ŋudzɔnɔnɔ: Mɔnu sia bia be woanɔ ŋku lém ɖe kansa la ŋu nyuie to edodokpɔ kple dodokpɔwo wɔwɔ edziedzi me, gake womadze dɔdamɔnu gɔme o negbe ɖe dzesiwo dze alo wotrɔ ko.
Ate ŋu asɔ na ŋutsu tsitsi siwo ŋu tsinyegoe me kansa si le tsitsim blewu le kple esiwo ŋu lãmesẽkuxi sesẽ bubuwo le.
Ele vevie be nàdzro atikewɔmɔnu vovovo siwo li la me kple atikewɔlawo be woanya atikewɔmɔnu nyuitɔ si li na ame ɖesiaɖe.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Mɔxeɖenu: atikewɔwɔ']
['Taɖodzinu siwo nye nufiafia kple nyatakaka koe le nyatakakadzraɖoƒe sia ŋu eye menye atikewɔwɔ ŋuti ɖaŋuɖoɖo alo dɔwɔnawo ƒe nya gblɔm wole o.']
['Mele be woazã nyatakaka siwo wona la atsɔ ada dɔléle alo dɔ aɖe o, eye ele be amesiwo di be yewoakpɔ atikewɔwɔ ŋuti ɖaŋuɖoɖo na yewo la nabia ɖɔkta si xɔ mɔɖegbalẽ.']
['De dzesii be neural network si wɔa nyabiabiawo ƒe ŋuɖoɖowo la meɖia o vevietɔ ne wotsɔ xexlẽdzesiwo wɔe. Le kpɔɖeŋu me, ne wotsɔ ame siwo ŋu dɔléle aɖe le ƒe xexlẽme wɔ dɔe.']
['Bia wò ɖɔkta alo lãmesẽdɔwɔla bubu si dze ƒe aɖaŋuɖoɖo ɣesiaɣi le lãmesẽkuxi aɖe ŋu. Mègaŋe aɖaba ƒu aɖaŋuɖoɖo si ɖɔktawo ɖo na wò alo gbɔ dzi ɖi le exexlẽ me le nyatakakadzraɖoƒe sia ta o. Ne èsusu be ɖewohĩ lãmesẽkuxi aɖe le fu ɖem na ye la, ke yɔ 911 alo yi ɖe afisi wokpɔa nɔnɔme kpatawo gbɔ le.']
['Copyright: Copyright']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) na mɔ siwo dzi copyright ƒe nunɔlawo ate ŋu ato awɔ nu ɖe nu siwo wo xɔ se be wo le Internet dzi la ŋu.']
['Ne èxɔe se kple kakaɖedzi be nyatakakadzraɖoƒe alo dɔwɔnu aɖe si míetsɔ wɔ míaƒe nyatakakadzraɖoƒea alo dɔwɔnawo la nye dada le wò gome la, wò ŋutɔ (alo wò dɔtɔ) ate ŋu aŋlɔ agbalẽ aɖo ɖe mí abia be míaɖe nyatakakadzraɖoƒea alo dɔwɔnua ɖa alo axe mɔ ɖe ezazã nu.']
['Ele be woana nyatakakawo to e-mail dzi (kpɔ "Kpekpeɖeŋunaƒe" ƒe akpa si nye e-mail adrɛs). ']
['DMCA bia be nàŋlɔ nyatakaka siwo gbɔna ɖe wò nyatakaka si nèŋlɔ be woada le copyright dzi la me: (1) nuŋɔŋlɔ si fia be copyright le dɔ si ŋu wole nu ƒom le la ŋu; (2) nyatakaka si fia be nuŋɔŋlɔa le eme eye wòade mía nu be míake ɖe eŋu; (3) nyatakaka siwo ana míake ɖe ŋuwò, siwo dometɔ aɖewoe nye wò adrɛs, kaƒodzesi kple e-mail adrɛs; (4) wò nya si fia be èxɔe se kple kakaɖedzi be copyright ƒe ame si tɔe nyatakakaa nye, alo eƒe dɔtɔ, alo se aɖeke meɖe mɔ ɖe eŋu o; ']
['(5) Wò ŋutɔ nàŋlɔ agbalẽ si dzi nàde asii, si me nàde se be ne mèwɔe o la, àda alakpa, atsɔ aɖo kpe edzi be nyatakaka siwo le nyatakakaa me la de pɛpɛpɛ eye be ŋusẽ le asiwò be nàʋli agbalẽ siwo ŋu wogblɔ le be woda le la ta.']
['Eye (6) ame si tɔe agbalẽa nye alo ame si wona ŋusẽe be wòawɔ dɔ le ame si tɔ ŋkɔ me la ƒe asinuŋɔŋlɔ alo eƒe asinuŋɔŋlɔ si le mɔ̃ dzi. ']
['Ne mèŋlɔ nyatakaka siwo katã le etame ɖe agbalẽa me o la, ate ŋu ana be wò nyatoƒoe me dzodzro natsi megbe.']
['Kadodo']
['Taflatse ɖo email ɖe mí ne nyabiabia alo aɖaŋuɖoɖo aɖe le asiwò.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Le Eŋu']
['BioMedLib zãa kɔmpiuta siwo wɔa dɔ le wo ɖokui si (mɔ̃ siwo zãa mɔ̃ɖaŋunuwo tsɔ srɔ̃a nu) tsɔ wɔa nyabiabia kple ŋuɖoɖowo.']
